Sanofi’s Tolebrutinib Receives FDA Breakthrough Therapy Designation for nrSPMS
Sanofi ( (SNY) ) has issued an announcement. Sanofi announced that the FDA has granted Breakthrough Therapy designation to tolebrutinib for treating non-relapsing secondary progressive multiple ...
Multiple Sclerosis News Today4d
Tolebrutinib for SPMS granted FDA breakthrough therapy designation
Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...
Hosted on MSN7d
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...
Monthly Prescribing Reference7d
Tolebrutinib Gets Breakthrough Tx Status for Non-Relapsing Secondary Progressive MS
The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.
Daily4d
Sanofi gets USFDA Breakthrough Therapy designation for multiple sclerosis therapy Tolebrutinib
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Business Insider8d
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with ...
The Pharma Letter8d
FDA status for Sanofi’s tolebrutinib in non-relapsing secondary progressive MS
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...
Sanofi's Tolebrutinib Gets FDA Breakthrough Therapy Designation For NrSPMS
French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
Yahoo Finance8d
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
Designation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS) Tolebrutinib is the first and only brain-penetrant ...
PharmiWeb8d
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).